



## **Press Release**

### **Eurocor's partner Micell Technologies reported preclinical data for MiStent™ Drug-Eluting Coronary Stent at EuroPCR**

**Bengaluru, India | Bonn, Germany, May 27<sup>th</sup>, 2011** - Eurocor GmbH is pleased to announce that their partner Micell Technologies presented positive preclinical data at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled: "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities."

The MiStent Drug-Eluting Coronary Stent System ("MiStent DES") is an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation.

In a porcine coronary model, data show continuous and controlled release of Sirolimus, with the MiStent DES coating being eliminated from the stent within 45 to 60 days and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott MULTI-LINK Vision™ Coronary Stent at 30 and 90 days in the challenging overlapping stents implant configuration.

Sreerangan Kurup, Managing Director of Eurocor GmbH: "Our collaboration with Micell Technologies is bringing together the expertise of both companies to produce a fundamentally different DES. This important and encouraging data underscores the potential overall safety profile and efficacy of MiStent DES."

Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 mm to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured with angiography in treated de novo lesions



ranging in diameter from 2.5 mm to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.

In 2009, Maxcor Lifescience, Inc., a subsidiary of Opto Circuits (India) Ltd. entered into a strategic cooperation agreement with Micell Technologies for developing and commercializing leading edge Rapamycin (Sirolimus) – coronary based drug-eluting stents (DES) and drug-eluting balloons (DEB).

-End-

#### **About: MiStent DES**

The MiStent DES is a drug-eluting stent designed to optimize healing. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration. The MiStent DES is intended to deliver a precise therapeutic solution for coronary artery disease with the potential to avoid the long-term safety concerns associated with current drug-eluting stents.

Using an approved drug (Sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days.

In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES currently is being evaluated in international clinical studies.

The MiStent Drug Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

#### **About: Micell Technologies Inc.**

Micell Technologies is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-coated balloon for vascular interventions. Visit them at [www.micell.com](http://www.micell.com).

The MiStent Drug Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

Micell, Micell Technologies, the Micell Logo, and MiStent DES are among the trademarks of Micell Technologies, Inc.

#### **About: Eurocor GmbH**

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead™ – with innovative products such as DIOR® and FREEWAY™. Eurocor GmbH is an Opto Circuits (India) Ltd. Company.

For more information, please visit [eurocor.de](http://eurocor.de) and [optocircuits.com](http://optocircuits.com).

**Eurocor GmbH**  
One heartbeat ahead™

**Eurocor GmbH**  
Rheinwerkallee 2  
82353227 Bonn  
Germany

T + 49 (0) 228 20 1500  
F + 49 (0) 228 20 1505  
[pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)  
[eurocor.de](http://eurocor.de)

Eurocor is subsidiary of  
Opto Circuits (India) Ltd  
[optocircuits.com](http://optocircuits.com)



**About: Opto Circuits (India) Limited**

Headquarters: Bengaluru, Karnataka, India

BSE: 532391 | NSE: OPTOCIRCU

Website: [www.optocircuits.com](http://www.optocircuits.com)

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anaesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs. The company's key markets are North America, Europe and BRIC countries

**Media Contact**

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)